scholarly article | Q13442814 |
P50 | author | Katherine A. High | Q41502889 |
P2093 | author name string | Hua Li | |
Hildegund C J Ertl | |||
Weidong Xiao | |||
Dongming Zhou | |||
Te-Lang Wu | |||
Wynetta Giles-Davis | |||
Steven Tuyishime | |||
P2860 | cites work | Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy | Q41999615 |
Cross-presentation of adeno-associated virus serotype 2 capsids activates cytotoxic T cells but does not render hepatocytes effective cytolytic targets | Q42613058 | ||
Stimulation history dictates memory CD8 T cell phenotype: implications for prime-boost vaccination | Q43725424 | ||
CD8(+) T-cell responses to adeno-associated virus capsid in humans | Q45406111 | ||
Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector | Q45855552 | ||
Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector | Q45862203 | ||
Pre-existing AAV capsid-specific CD8+ T cells are unable to eliminate AAV-transduced hepatocytes | Q45865401 | ||
Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy | Q45884700 | ||
Challenges of immune responses in gene replacement therapy. | Q51989357 | ||
Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles | Q56897778 | ||
Identification of conserved T cell receptor CDR3 residues contacting known exposed peptide side chains from a major histocompatibility complex class I-bound determinant | Q57082205 | ||
Adeno-associated virus serotype 2 induces cell-mediated immune responses directed against multiple epitopes of the capsid protein VP1 | Q24634560 | ||
In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens | Q29615098 | ||
Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response | Q29619095 | ||
Identification of mouse AAV capsid-specific CD8+ T cell epitopes | Q33226431 | ||
Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles | Q33337378 | ||
A preclinical animal model to assess the effect of pre-existing immunity on AAV-mediated gene transfer | Q33713730 | ||
A prescription for human immunology | Q34001827 | ||
Antigen decoding by T lymphocytes: from synapses to fate determination | Q34263452 | ||
Self-complementary AAV vectors; advances and applications | Q34804660 | ||
Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo | Q35914452 | ||
The proteasome and MHC class I antigen processing | Q35967572 | ||
Recombinant adeno-associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice | Q36144935 | ||
New recombinant serotypes of AAV vectors. | Q36172991 | ||
Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1. | Q36438711 | ||
Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses | Q36685842 | ||
Immune responses to AAV in clinical trials | Q36990095 | ||
Cellular immune response to cryptic epitopes during therapeutic gene transfer | Q37250034 | ||
AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells | Q37348251 | ||
Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy | Q37364038 | ||
Targeting of antigen to the herpesvirus entry mediator augments primary adaptive immune responses | Q37712554 | ||
Antigen presenting cells | Q38644205 | ||
Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses | Q39501488 | ||
Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo | Q39860625 | ||
P433 | issue | 3 | |
P921 | main subject | vector-borne disease | Q2083837 |
P304 | page(s) | 536-546 | |
P577 | publication date | 2010-12-14 | |
P1433 | published in | Molecular Therapy | Q15762400 |
P1476 | title | Adeno-associated virus vectors serotype 2 induce prolonged proliferation of capsid-specific CD8+ T cells in mice | |
P478 | volume | 19 |
Q37690476 | CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors' genome. |
Q35568563 | Capsid-specific T-cell responses to natural infections with adeno-associated viruses in humans differ from those of nonhuman primates |
Q36595639 | Efficacy and Safety of rAAV2-ND4 Treatment for Leber's Hereditary Optic Neuropathy |
Q47554736 | Emerging Issues in AAV-Mediated In Vivo Gene Therapy |
Q36709834 | Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. |
Q57803544 | Exposure to wild-type AAV drives distinct capsid immunity profiles in humans |
Q36295934 | Gene Therapy for Duchenne muscular dystrophy |
Q92863312 | Immune Response Mechanisms against AAV Vectors in Animal Models |
Q36983740 | Immune responses to AAV vectors: overcoming barriers to successful gene therapy |
Q36848699 | Kinetics of adeno-associated virus serotype 2 (AAV2) and AAV8 capsid antigen presentation in vivo are identical |
Q39553052 | Liver-Directed Adeno-Associated Viral Gene Therapy for Hemophilia |
Q41907025 | Modulation of CD8+ T cell responses to AAV vectors with IgG-derived MHC class II epitopes |
Q92940638 | Muscle-Directed Delivery of an AAV1 Vector Leads to Capsid-Specific T Cell Exhaustion in Nonhuman Primates and Humans |
Q38191212 | Pre-Clinical Assessment of Immune Responses to Adeno-Associated Virus (AAV) Vectors |
Q61811175 | Protein-Engineered Coagulation Factors for Hemophilia Gene Therapy |
Q40282843 | Regulatory and Exhausted T Cell Responses to AAV Capsid. |
Q24625426 | Self-complementary AAVs induce more potent transgene product-specific immune responses compared to a single-stranded genome |
Q40458807 | Synergistic inhibition of PARP-1 and NF-κB signaling downregulates immune response against recombinant AAV2 vectors during hepatic gene therapy. |
Q36155013 | The threefold protrusions of adeno-associated virus type 8 are involved in cell surface targeting as well as postattachment processing |
Q96109656 | Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates |
Q36143384 | Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates |
Q95271852 | Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A |
Q40073271 | Unraveling the complex story of immune responses to AAV vectors trial after trial |
Search more.